ArticleCommunications medicine2025
Longitudinal evaluation of serum cholinesterase benefits prognosis surveillance of common types of human cancer.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExisting literature on serum cholinesterase (ChE) in cancer prognosis have predominantly evaluated preoperative levels, ignoring serial ChE measurements during postoperative follow-up.
methods5925 patients undergoing curative resection for stage I-III non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) were retrospectively included. Patients were divided into persistently normal, normalized, lowered and persistently low perioperative ChE patterns, as well as longitudinal ChE trajectories identified by the latent class growth mixed model (LCGMM). The associations of ChE dynamic changes with overall survival (OS) and recurrence-free survival (RFS) were evaluated.
resultsPostoperative ChE emerged as an independent prognostic factor, event after accounting for preoperative levels. Perioperative ChE stratification revealed divergent survival outcomes: the persistently normal group (82.5%) demonstrated 8.6% higher 5-year OS rate than the lowered group (73.9%), while the normalized group (73.3%) had 13.9% higher 5-year OS rate than the persistently low group (59.4%). LCGMM identified three distinct longitudinal trajectories: slow-rising (5-year OS rate: 79.7%; reference group), rising-decreasing (5-year OS rate: 64.8%; adjusted HR: 1.50, 95% CI: 1.14 to 1.99) and decreasing-rising (5-year OS rate: 58.1%; adjusted HR: 2.33, 95% CI: 1.69 to 3.22). Consistent results were observed for RFS as well. Furthermore, stratified analyses confirmed statistically significant associations of ChE dynamic changes with prognosis across all histological subtypes.
conclusionsA routine follow-up measurement of postoperative ChE was recommended to improve individualized management of cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.